Skip to main content
Premium Trial:

Request an Annual Quote

Aetna, Cigna, UnitedHealthcare to Cover Agendia's MammaPrint

NEW YORK (GenomeWeb) – Agendia announced today that its MammaPrint 70-gene signature breast cancer recurrence risk test has received positive coverage decisions from Aetna, Cigna, and UnitedHealthcare.

According to Agendia, the three insurers cover more than 85 million people in the US and internationally.

"The positive coverage decisions by these major healthcare insurers echo the rapidly increasing adoption of MammaPrint among US physicians who recognize the value of the test to personalize and, in many cases, de-escalate treatment for early breast cancer," Agendia Chief Medical Officer William Audeh said in a statement. "MammaPrint provides physicians with a binary low risk or high risk of recurrence result that has considerable quality of life and cost-saving implications."

Last year, Blue Shield of California and First Coast Service Options — the Medicare contractor for Florida, Puerto Rico, and the Virgin Islands — began covering MammaPrint. Also in 2017, the American Society of Clinical Oncology published revised early-stage breast cancer guidelines that feature a focused update recommending MammaPrint for guiding treatment decisions in early-stage breast cancer patients with one-to-three positive lymph nodes.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.